Navlimetostat

Navlimetostat
Clinical data
Other namesMRTX-1719
Identifiers
  • (2M)-2-{4-[4-(Aminomethyl)-1-oxo-1,2-dihydrophthalazin-6-yl]-1-methyl-1H-pyrazol-5-yl}-4-chloro-6-(cyclopropyloxy)-3-fluorobenzonitrile
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
PDB ligand
Chemical and physical data
FormulaC23H18ClFN6O2
Molar mass464.89 g·mol−1
3D model (JSmol)
  • CN1C(=C(C=N1)C2=CC3=C(C=C2)C(=O)NN=C3CN)C4=C(C(=CC(=C4F)Cl)OC5CC5)C#N
  • InChI=InChI=1S/C23H18ClFN6O2/c1-31-22(20-15(8-26)19(33-12-3-4-12)7-17(24)21(20)25)16(10-28-31)11-2-5-13-14(6-11)18(9-27)29-30-23(13)32/h2,5-7,10,12H,3-4,9,27H2,1H3,(H,30,32)
  • Key:BZKIOORWZAXIBA-UHFFFAOYSA-N

Navlimetostat is an investigational new drug that is being evaluated by Mirati Therapeutics abd Bristol-Myers Squibb for the treatment of adenocarcinoma. It is a PRMT5 protein inhibitor.